{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:10:40Z","timestamp":1782177040808,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["ICMRCAREP\/2023\/0000517"],"award-info":[{"award-number":["ICMRCAREP\/2023\/0000517"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cca.2025.120349","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T23:14:10Z","timestamp":1746573250000},"page":"120349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Tailored pharmacotherapy monitoring in Parkinson\u2019s disease and Schizophrenia using a rapid and sensitive \u03b1-Synuclein assay"],"prefix":"10.1016","volume":"574","author":[{"given":"Neelam","family":"Upadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjari","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Kumar","family":"Chaddha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunmozhimaran","family":"Elavarasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gururao","family":"Hariprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravikrishnan","family":"Elangovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2025.120349_b0005","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1111\/febs.14607","article-title":"Determinants of dopaminergic neuron loss in Parkinson's disease","volume":"285","author":"Surmeier","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.cca.2025.120349_b0010","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/pharmaceutics15051503","article-title":"The management of Parkinson\u2019s disease: an overview of the current advancements in drug delivery systems","volume":"15","author":"Nakmode","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cca.2025.120349_b0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/pharmaceutics15030839","article-title":"Development of small molecules targeting \u03b1-synuclein aggregation: A promising strategy to treat Parkinson\u2019s Disease","volume":"15","author":"Pe\u00f1a-D\u00edaz","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cca.2025.120349_b0020","unstructured":"Hany M., Rehman B., Rizvi A., Chapman J., Schizophrenia, StatPearls [Internet] (2025) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539864\/."},{"key":"10.1016\/j.cca.2025.120349_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2022-100823","article-title":"A glimpse of gender differences in schizophrenia","volume":"35","author":"Li","year":"2022","journal-title":"General Psychiatry"},{"key":"10.1016\/j.cca.2025.120349_b0030","article-title":"The role of dopamine and its dysfunction as a consequence of oxidative stress","volume":"2016","author":"Olgu\u00edn","year":"2016","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.cca.2025.120349_b0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41537-024-00439-3","article-title":"Parkinson\u2019s disease and schizophrenia interactomes contain temporally distinct gene clusters underlying comorbid mechanisms and unique disease processes","volume":"10","author":"Karunakaran","year":"2024","journal-title":"Schizophrenia"},{"key":"10.1016\/j.cca.2025.120349_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.prdoa.2023.100212","article-title":"Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment","volume":"9","author":"Isaacson","year":"2023","journal-title":"Clin. Parkinsonism Related Disorder"},{"key":"10.1016\/j.cca.2025.120349_b0045","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.cca.2025.120349_b0050","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41398-022-02233-0","article-title":"The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia","volume":"12","author":"Xu","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.cca.2025.120349_b0055","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: A review","volume":"311","author":"Connolly","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.cca.2025.120349_b0060","first-page":"179","article-title":"Idiopathic Parkinson\u2019s disease and schizophrenia: dilemma in diagnosis and treatment of a case","volume":"14","author":"Sharma","year":"2019","journal-title":"Iran. J. Psychiatry"},{"key":"10.1016\/j.cca.2025.120349_b0065","article-title":"Dopamine based pharmaco-therapeutics of schizophrenia and Parkinson\u2019s disease: two ends of one spectrum","volume":"2","author":"Hariprasad","year":"2017","journal-title":"Ann. Pharmacol. Pharm."},{"key":"10.1016\/j.cca.2025.120349_b0070","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/mds.25129","article-title":"Dopamine agonists and delusional jealousy in Parkinson\u2019s disease: A cross-sectional prevalence study","volume":"27","author":"Poletti","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cca.2025.120349_b0075","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/mds.20582","article-title":"Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson\u2019s disease","volume":"20","author":"Pacchetti","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cca.2025.120349_b0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/08919887211018280","article-title":"Psychosis in Parkinson\u2019s disease: current treatment options and impact on patients and caregivers","volume":"34","author":"Segal","year":"2021","journal-title":"J. Geriatr. Psychiatry Neurol"},{"key":"10.1016\/j.cca.2025.120349_b0085","article-title":"Extrapyramidal Symptoms in Patients Treated with Antipsychotic Drugs","volume":"09","author":"Werner","year":"2017","journal-title":"J Bioequivalence Bioavailab"},{"key":"10.1016\/j.cca.2025.120349_b0090","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/070674379403900203","article-title":"Remington, Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms","volume":"39","author":"Bezchlibnyk-Butler","year":"1994","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.cca.2025.120349_b0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics\u00a0: incidence, prevention and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.cca.2025.120349_b0100","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2147\/NDT.S205550","article-title":"Evaluation of \u03b1-synuclein and apolipoprotein e as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of parkinson\u2019s diseaseand schizophrenia","volume":"15","author":"Gupta","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.cca.2025.120349_b0105","doi-asserted-by":"crossref","DOI":"10.1177\/1179573518803585","article-title":"Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson\u2019s disease: A Preliminary Study","volume":"10","author":"Gupta","year":"2018","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.1016\/j.cca.2025.120349_b0110","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/NDT.S198559","article-title":"2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson\u2019s disease and schizophrenia","volume":"15","author":"Gupta","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.cca.2025.120349_b0115","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.2147\/NDT.S214217","article-title":"Cerebrospinal fluid proteomics for identification of \u03b12-macroglobulin as a potential biomarker to monitor pharmacological therapeutic efficacy in dopamine dictated disease states of Parkinson\u2019s disease and schizophrenia","volume":"15","author":"Gupta","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.cca.2025.120349_b0120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","article-title":"\u03b1-Synuclein in synaptic function and dysfunction","volume":"46","author":"Sharma","year":"2023","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.cca.2025.120349_b0125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/mds.28941","article-title":"Alpha and beta synucleins: from pathophysiology to clinical application as biomarkers","volume":"37","author":"Barba","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cca.2025.120349_b0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cca.2025.120349_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105966","article-title":"Monitoring \u03b1-synuclein aggregation","volume":"176","author":"Estaun-Panzano","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cca.2025.120349_b0140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/acn3.729","article-title":"Plasma alpha-synuclein detected by single molecule array is increased in PD","volume":"6","author":"Ng","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.cca.2025.120349_b0145","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","volume":"18","author":"Concha-Marambio","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.cca.2025.120349_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2023.115082","article-title":"Development of sensitive magnetic nanoparticle assisted rapid sandwich assay(s-MARSA) to monitor Parkinson\u2019s disease and Schizophrenia pharmacotherapy","volume":"667","author":"Upadhyay","year":"2023","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.cca.2025.120349_b0155","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1682\/JRRD.2011.06.0103","article-title":"The Unified Parkinson\u2019s Disease Rating Scale as a predictor of peak aerobic capacity and ambulatory function","volume":"49","author":"Ivey","year":"2012","journal-title":"J. Rehabil. Res. Dev."},{"key":"10.1016\/j.cca.2025.120349_b0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/08039480510027698","article-title":"Reliability of clinical ICD-10 schizophrenia diagnoses","volume":"3","author":"Jakobsen","year":"2005","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.cca.2025.120349_b0165","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association declaration of Helsinki","year":"2013","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.cca.2025.120349_b0170","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","article-title":"A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking","volume":"73","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2025.120349_b0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/pr800545q","article-title":"Standard operating procedures for serum and plasma collection: Early detection research network consensus statement standard operating procedure integration working group","volume":"8","author":"Tuck","year":"2009","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cca.2025.120349_b0180","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson\u2019s disease in women and men: what\u2019s the difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.cca.2025.120349_b0185","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","article-title":"Age at onset and Parkinson disease phenotype","volume":"86","author":"Pagano","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2025.120349_b0190","article-title":"Quality of life in schizophrenia patients with and without adequate pharmaceutical care: A randomized controlled study","volume":"20","author":"Joshi","year":"2023","journal-title":"Clin. Epidemiol. Global Health"},{"key":"10.1016\/j.cca.2025.120349_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5599\/admet.3.1.159","article-title":"Expression and transport of \u03b1-synuclein at the blood-cerebrospinal fluid barrier and effects of manganese exposure","volume":"3","author":"Bates","year":"2015","journal-title":"ADMET DMPK"},{"key":"10.1016\/j.cca.2025.120349_b0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.peptides.2014.09.018","article-title":"Alpha synuclein is transported into and out of the brain by the blood-brain barrier","volume":"62","author":"Sui","year":"2014","journal-title":"Peptides (N.Y.)"},{"key":"10.1016\/j.cca.2025.120349_b0205","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2025.120349_b0210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s40478-024-01873-1","article-title":"A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson\u2019s disease","volume":"12","author":"Wang","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.cca.2025.120349_b0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","article-title":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease","volume":"11","author":"Majbour","year":"2016","journal-title":"Mol. Neurodegeneration"},{"issue":"13","key":"10.1016\/j.cca.2025.120349_b0220","doi-asserted-by":"crossref","first-page":"13815","DOI":"10.1039\/D2SC00066K","article-title":"An antibody scanning method for the detection of \u03b1-synuclein oligomers in the serum of Parkinson's disease patients","volume":"13","author":"Kulenkampff","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.cca.2025.120349_b0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neulet.2015.05.030","article-title":"Detection of \u03b1-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease","volume":"599","author":"Wang","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2025.120349_b0230","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s13760-023-02452-2","article-title":"Alpha-synuclein in peripheral body fluid as a biomarker for Parkinson's disease","volume":"124","author":"Shu","year":"2024","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.cca.2025.120349_b0235","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00401-009-0492-5","article-title":"Lewy body\/\u03b1-synucleinopathy in schizophrenia and depression: a preliminary neuropathological study","volume":"117","author":"Jellinger","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cca.2025.120349_b0240","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/eip.13398","article-title":"Decreased serum levels of \u03b1-synuclein in patients with schizophrenia and their unaffected siblings","volume":"17","author":"G\u00f6verti","year":"2023","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.cca.2025.120349_b0245","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","article-title":"Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis","volume":"99","author":"Zubelzu","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.cca.2025.120349_b0250","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3233\/JPD-212694","article-title":"Comparison of different platform immunoassays for the measurement of plasma alpha-synuclein in Parkinson's Disease patients","volume":"11","author":"Youssef","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.cca.2025.120349_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101336","article-title":"Post-translational modifications: Regulators of neurodegenerative proteinopathies","volume":"68","author":"Gupta","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.cca.2025.120349_b0260","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5483\/BMBRep.2022.55.7.073","article-title":"Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease","volume":"55","author":"Yoo","year":"2022","journal-title":"BMB Rep."},{"key":"10.1016\/j.cca.2025.120349_b0265","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.nbd.2013.12.011","article-title":"Enhanced ubiquitin-dependent degradation by Nedd4 protects against \u03b1-synuclein accumulation and toxicity in animal models of Parkinson's disease","volume":"64","author":"Davies","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cca.2025.120349_b0270","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4103\/1673-5374.162763","article-title":"The E3 ubiquitin ligase seven in absentia homolog 1 may be a potential new therapeutic target for Parkinson's disease","volume":"10","author":"Cai","year":"2015","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.cca.2025.120349_b0275","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbrc.2020.04.091","article-title":"Interaction of the chaperones alpha B-crystallin and CHIP with fibrillar alpha-synuclein: Effects on internalization by cells and identification of interacting interfaces","volume":"527","author":"Bendifallah","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2025.120349_b0280","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1073\/pnas.1808845116","article-title":"R., \u03b1-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease","volume":"116","author":"Levine","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cca.2025.120349_b0285","doi-asserted-by":"crossref","first-page":"47746","DOI":"10.1074\/jbc.M408906200","article-title":"Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation","volume":"279","author":"Hodara","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2025.120349_b0290","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jns.2011.04.015","article-title":"Proteasome inhibition induces \u03b1-synuclein SUMOylation and aggregate formation","volume":"307","author":"Kim","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cca.2025.120349_b0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1083\/jcb.201010117","article-title":"Sumoylation inhibits alpha-synuclein aggregation and toxicity","volume":"194","author":"Krumova","year":"2011","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.cca.2025.120349_b0300","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/mds.21007","article-title":"Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients","volume":"21","author":"Chiba-Falek","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.cca.2025.120349_b0305","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1523\/JNEUROSCI.6119-09.2010","article-title":"Methylation regulates alpha-synuclein expression and is decreased in Parkinson\u2019s disease patients\u2019 brains","volume":"30","author":"Jowaed","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cca.2025.120349_b0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015522","article-title":"CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson\u2019s disease","volume":"5","author":"Matsumoto","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2025.120349_b0315","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchemneu.2011.01.005","article-title":"MicroRNAs in Parkinson\u2019s disease","volume":"42","author":"Harraz","year":"2011","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.cca.2025.120349_b0320","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.febslet.2014.12.014","article-title":"Inhibition of miR-34b and miR-34c enhances \u03b1-synuclein expression in Parkinson\u2019s disease","volume":"589","author":"Kabaria","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cca.2025.120349_b0325","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1089\/gtmb.2010.0050","article-title":"Alpha-and beta-synucleins mRNA expression in lymphocytes of schizophrenia patients","volume":"14","author":"Noori-Daloii","year":"2010","journal-title":"Genet. Test. Mol Biomarkers"},{"key":"10.1016\/j.cca.2025.120349_b0330","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4306\/pi.2017.14.3.344","article-title":"Decreased expression of \u03b1-synuclein, Nogo-A and UCH-L1 in patients with schizophrenia: A preliminary serum study","volume":"14","author":"Demirel","year":"2017","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.cca.2025.120349_b0335","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cca.2025.120349_b0340","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1176\/appi.ajp.2007.07040715","article-title":"Presentation and management of psychosis in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"164","author":"Weintraub","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cca.2025.120349_b0345","article-title":"Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: Results from the Global Burden of Disease Study 2017","author":"He","year":"2019","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.cca.2025.120349_b0350","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.cca.2025.120349_b0355","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3390\/bios11100402","article-title":"Enhanced plasmonic biosensor utilizing paired antibody and label-free fe3o4 nanoparticles for highly sensitive and selective detection of parkinson\u2019s \u03b1-synuclein in serum","volume":"11","author":"Mandala","year":"2021","journal-title":"Biosensors (Basel)"},{"key":"10.1016\/j.cca.2025.120349_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-016-0198-5","article-title":"Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles","volume":"14","author":"Yang","year":"2016","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.cca.2025.120349_b0365","doi-asserted-by":"crossref","first-page":"33691","DOI":"10.1074\/jbc.M112.379792","article-title":"Weiss, novel one-step immunoassays to quantify \u03b1-synuclein: applications for biomarker development and high-throughput screening","volume":"287","author":"Bidinosti","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2025.120349_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2020.112433","article-title":"Label-free immunodetection of \u03b1-synuclein by using a microfluidics coplanar electrolyte-gated organic field-effect transistor","volume":"167","author":"Ricci","year":"2020","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.cca.2025.120349_b0375","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00604-014-1180-2","article-title":"A porous silicon immunoassay platform for fluorometric determination of \u03b1-synuclein in human cerebrospinal fluid","volume":"181","author":"Lee","year":"2014","journal-title":"Microchim. Acta"},{"key":"10.1016\/j.cca.2025.120349_b0380","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1039\/D1RA06437A","article-title":"Sensitive immunosensing of \u03b1-synuclein protein in human plasma samples using gold nanoparticles conjugated with graphene: an innovative immuno-platform towards early stage identification of Parkinson\u2019s disease using point of care (POC) analysis","volume":"12","author":"Aminabad","year":"2022","journal-title":"RSC Adv."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125002281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125002281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T07:52:07Z","timestamp":1748073127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125002281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":76,"alternative-id":["S0009898125002281"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120349","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailored pharmacotherapy monitoring in Parkinson\u2019s disease and Schizophrenia using a rapid and sensitive \u03b1-Synuclein assay","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120349","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120349"}}